

## 5-Minute Journal Club: Defining the Current and Future Role of TROP2-Directed Antibody-Drug Conjugates in Breast Cancer — Issue 2

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- The ongoing Phase II DATO-BASE trial is investigating datopotamab deruxtecan in which of the following settings?**
  - In combination with an immune checkpoint inhibitor as neoadjuvant therapy for localized triple-negative breast cancer
  - As adjuvant therapy after pathologic complete response for HR-positive, HER2-negative breast cancer
  - In combination with a CDK4/6 inhibitor for HR-positive, HER2-negative breast cancer
  - For patients with breast cancer and brain metastases or leptomeningeal disease
- The Phase II PRIMED study demonstrated that appropriate prophylaxis improved which of the following side effects associated with sacituzumab govitecan?**
  - Diarrhea
  - Neutropenia
  - Both a and b
  - Neither a nor b
- Datopotamab deruxtecan should be permanently discontinued if patients develop interstitial lung disease that is ...**
  - Grade 1 or higher
  - Grade 2 or higher
  - Grade 3 or higher
  - Grade 4
- Which of the following strategies is recommended as prophylaxis for oral mucositis/stomatitis associated with datopotamab deruxtecan?**
  - Systemic corticosteroids
  - Antifungal oral suspension
  - Steroid-containing mouthwash
  - Antiviral therapy
- Which of the following strategies is recommended as prophylaxis for ocular surface events associated with datopotamab deruxtecan?**
  - Systemic corticosteroids
  - Oral omega-3 fatty acid supplementation
  - Antihistamine eye drops
  - Artificial tears